New drug aims to save eyes from advanced melanoma
NCT ID NCT06414590
Summary
This study is testing whether a drug called tebentafusp can shrink large, inoperable eye melanoma tumors before patients receive standard surgery or radiation. The drug works by guiding the body's immune cells to attack the cancer. The main goal is to see if shrinking the tumor first can help patients avoid having their entire eye removed and better control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED UNRESECTABLE UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Sidney Kimmel Cancer Center at Thomas Jefferson University
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Wills Eye Hospital
ACTIVE_NOT_RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Conditions
Explore the condition pages connected to this study.